Phase II Trial of Paclitaxel Combined With Trastuzumab and Pertuzumab as Pre-Operative Therapy for Inflammatory Breast Cancer
Latest Information Update: 04 Oct 2024
At a glance
- Drugs Paclitaxel (Primary) ; Pertuzumab (Primary) ; Trastuzumab (Primary) ; Cyclophosphamide; Doxorubicin
- Indications Early breast cancer; HER2 positive breast cancer; Inflammatory breast cancer; Male breast cancer
- Focus Therapeutic Use
- 30 Sep 2024 Planned End Date changed from 1 Jul 2024 to 1 Nov 2024.
- 15 May 2024 Planned End Date changed from 1 Mar 2024 to 1 Jul 2024.
- 17 Jul 2023 Planned End Date changed from 1 Mar 2023 to 1 Mar 2024.